Dana’s Angels Research Trust (DART), the nonprofit organization dedicated to funding medical research, education and treatment of the rare childhood disease Niemann-Pick Type C (NPC), often referred to as “childhood Alzheimer’s,” had the most perfect fall day for its 8th annual DART to the Finish Charity Walk, held Saturday, October 4, 2025 at Greenwich Point …
Category
Showing: 4 - 6 of 8 RESULTS
Banner News
Azafaros Secures €132M in Financing to advance Phase 3 clinical programs, including NPC
13 May 2025 Leiden, Netherlands, 13 May 2025 – Azafaros, a clinical-stage company focused on developing disease-modifying therapeutics to offer new treatment options to patients with rare lysosomal storage disorders, announces the completion of an oversubscribed €132M Series B financing led by Jeito Capital, co-led by Forbion Growth and with additional participation from Seroba, Pictet Group …
Zevra Therapeutics to Sell Priority-Review Voucher for $150 Million related to NPC drug approval
February 27, 2025 at 7:31 AM EST CELEBRATION, Fla., Feb. 27, 2025 (GLOBE NEWSWIRE) — Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with rare disease, today announced that it has entered into a definitive asset purchase agreement to sell its Rare Pediatric Disease …